Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Tech Today.
Press releases published on April 28, 2025
BPGbio CEO Dr. Niven R. Narain Named to The Medicine Maker Power List 2025
GlobeNewswire
·
April 28, 2025
BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered clinical-stage biopharma company, today announced that President and CEO Niven R. Narain, Ph.D. has been named to The Medicine Maker’s Power List 2025. The annual list …
Hudbay’s Eugene Lei wins Globe and Mail’s Report on Business 2025 Best Executive Award
GlobeNewswire
·
April 28, 2025
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Hudbay Minerals Inc. (“Hudbay” or the “Company”) (TSX, NYSE: HBM) is pleased to announce that Eugene Lei, Chief Financial Officer at Hudbay, has been recognized as a winner of the Globe and Mail’s Report on …
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
GlobeNewswire
·
April 28, 2025
WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today …
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
GlobeNewswire
·
April 28, 2025
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first …
Atana Expands Sales Team, Welcomes New Leaders to Drive Continued Growth
GlobeNewswire
·
April 28, 2025
BELLEVUE, Wash., April 28, 2025 (GLOBE NEWSWIRE) -- Seeking to redefine workplace culture and training, Atana today announced that Deena Perro and Brett Seller have joined the company’s growing sales team as demand for its award-winning solutions increases …
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
GlobeNewswire
·
April 28, 2025
CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy CDK2 MGD delayed resistance to CDK4/6 …
AAVantgarde appoints Mr. Rasmus Holm-Jorgensen as Chief Financial Officer
GlobeNewswire
·
April 28, 2025
MILAN, April 28, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the appointment of Mr …
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
GlobeNewswire
·
April 28, 2025
VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28, 2025 ( …
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
GlobeNewswire
·
April 28, 2025
Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA’s Uniquely Efficient Internal R…
Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
GlobeNewswire
·
April 28, 2025
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified 5 of 7 best overall response evaluable patients …
Auron Presents Preclinical Data Highlighting the Activity of AUTX-703 in Prostate Cancer at 2025 AACR Annual Meeting
GlobeNewswire
·
April 28, 2025
NEWTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced preclinical data in prostate …
Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body™ Therapeutic, at AACR 2025
GlobeNewswire
·
April 28, 2025
Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional bispecific molecules – driving both adaptive and innate anti-tumor activity In multiple …
Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025
GlobeNewswire
·
April 28, 2025
BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter …
XORTX Announces Grant of European Patent
GlobeNewswire
·
April 28, 2025
CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
Roper Technologies announces first quarter financial results
GlobeNewswire
·
April 28, 2025
SARASOTA, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) reported financial results for the first quarter ended March 31, 2025. First quarter 2025 highlights Revenue increased 12% to $1.88 billion; acquisition contribution …
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
GlobeNewswire
·
April 28, 2025
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings support continued evaluation …
Azimut Arranges Strategic Investment by Centerra Gold
GlobeNewswire
·
April 28, 2025
LONGUEUIL, Québec, April 28, 2025 (GLOBE NEWSWIRE) -- Azimut Exploration Inc. (“Azimut” or the “Company”) (TSXV: AZM) (OTCQX: AZMTF) is pleased to announce that it has entered into a subscription agreement with Centerra Gold Inc. (“Centerra”) (TSX: CG) ( …
Azimut met en place un investissement stratégique par Centerra Gold
GlobeNewswire
·
April 28, 2025
LONGUEUIL, Québec, 28 avr. 2025 (GLOBE NEWSWIRE) -- Exploration Azimut Inc. (« Azimut » ou la « Société ») (TSXV : AZM; OTCQX : AZMTF) annonce que la Société a conclu une convention de souscription avec Centerra Gold Inc. (“Centerra”) (TSX: CG) (NYSE: CGAU …
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
GlobeNewswire
·
April 28, 2025
- The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date - In as few as 3 months, the time to first event (all-cause mortality ( …
Integral Metals Strengthens Advisory Board with Appointment of Former White House Advisor Evan “Thor” Torrens
GlobeNewswire
·
April 28, 2025
CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- Integral Metals Corp. (CSE: INTG | OTC: ITGLF | FSE: ZK9) (the “Company” or “Integral”) is pleased to announce the appointment of Evan “Thor” Torrens, Emmy Award-winning media expert, investor, and …